{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:31:36Z","timestamp":1763361096030,"version":"3.45.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Standard treatment for tuberculosis (TB) typically involves the use of four first-line medications, namely, pyrazinamide, isoniazid, rifampicin, and ethambutol. Rifafour is a tablet that consists of a combination of these four anti-TB medications. Immediate TB treatment, typically lasting up to 14\u00a0weeks in the hospital as an inpatient and up to 6\u00a0months as an outpatient, is imperative to kill the bacteria responsible for TB. However, the anti-TB medication itself is hepatotoxic and can cause several health concerns. To elucidate these metabolic consequences, this study used an untargeted\n                    <jats:sup>1<\/jats:sup>\n                    H-NMR metabolomics approach to investigate the systemic metabolic effects of anti-TB medication administered over 14\u00a0days to healthy Kramnik (C3HeB\/FeJ) mice \u2013 a mouse model commonly used in TB studies. Hippuric acid (p &amp;lt; 0.01), indoxyl sulfate (p &amp;lt; 0.05), phenylacetylglycine (p &amp;lt; 0.01), and tryptophan (p &amp;lt; 0.05) remained significantly decreased in the urine throughout the 14-day TB drug treatment period, whereas in the feces, choline (p &amp;lt; 0.05) and succinic acid (p &amp;lt; 0.01) remained consistently perturbed. Serum collected on day 14 showed significant (p &amp;lt; 0.05) concentrations of glucose, taurine, glycine, uracil, histamine, and allantoin, all of which were upregulated in the TB drug-treated group. This study implies that changes in systemic metabolism directly from TB treatment should be noted and considered when examining animals\/patients with active TB on similar TB treatment. That is, these findings highlight the need to distinguish drug-induced metabolic abnormalities from those resulting from infections, consequently aiding the interpretation of metabolomic data in tuberculosis research and improving the development of more accurate therapeutic and diagnostic approaches. Hence, future studies can focus on the perturbed metabolites from TB and account for metabolites resulting from anti-TB medication, as shown in this study.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2025.1661938","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:28:06Z","timestamp":1763360886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["1H-NMR-based metabolomics study of Rifafour in a healthy Kramnik (C3HeB\/FeJ) tuberculosis mouse model"],"prefix":"10.3389","volume":"16","author":[{"given":"Oluwadara Pelumi","family":"Omotayo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyethemba","family":"Bhengu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolandy","family":"Lemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kobus","family":"Venter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayne","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","first-page":"61","article-title":"The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis","volume":"79","author":"Blomberg","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clnesp.2024.10.148","article-title":"Metabolomics: unveiling biological matrices in precision nutrition and health","volume":"64","author":"Catussi","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.xpro.2023.102181","article-title":"1H-NMR protocol for rapid diagnosis of purine and pyrimidine metabolic disorders in urine","volume":"4","author":"Davoren","year":"2023","journal-title":"Star. Protoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/14787210.2024.2400536","article-title":"Decoding drug resistance in mycobacterium tuberculosis complex: genetic insights and future challenges","volume":"22","author":"Deshpande","year":"2024","journal-title":"Expert Rev. Anti-infective Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis","volume":"56","author":"Driver","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.chom.2014.11.003","article-title":"Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance","volume":"16","author":"Ferreyra","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0165787","DOI":"10.1371\/journal.pone.0165787","article-title":"Rifampicin-induced hepatic lipid accumulation: association with up-regulation of peroxisome proliferator-activated receptor \u03b3 in mouse liver","volume":"11","author":"Huang","year":"2016","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1152\/physiol.00005.2020","article-title":"Gut microbiota in liver disease: what do we know and what do we not know?","volume":"35","author":"Jiang","year":"2020","journal-title":"Physiology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.3390\/molecules23123087","article-title":"Metabolomic study to determine the mechanism underlying the effects of Sagittaria sagittifolia polysaccharide on isoniazid-and rifampicin-induced hepatotoxicity in mice","volume":"23","author":"Ke","year":"2018","journal-title":"Molecules"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1016\/j.lmd.2025.100059","article-title":"Plasma dynamic metabolomics during anti-tuberculosis treatment identifies an amino acid panel with diagnostic potential","volume":"2","author":"Li","year":"2025","journal-title":"LabMed Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.3390\/molecules29102198","article-title":"Metabolomics for clinical biomarker discovery and therapeutic target identification","volume":"29","author":"Lin","year":"2024","journal-title":"Molecules"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1071\/an20554","article-title":"Implications of elevated threonine plasma concentrations in the development of reduced-crude protein diets for broiler chickens","volume":"61","author":"Macelline","year":"2021","journal-title":"Animal Prod. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11306-018-1372-6","article-title":"Miniaturized 1H-NMR method for analyzing limited-quantity samples applied to a mouse model of Leigh disease","volume":"14","author":"Mason","year":"2018","journal-title":"Metabolomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111448","DOI":"10.1016\/j.cbi.2025.111448","article-title":"Endoplasmic reticulum stress inhibition preserves mitochondrial function and cell survival during the early onset of isoniazid-induced oxidative stress","volume":"411","author":"Nhung","year":"2025","journal-title":"Chemico-Biological Interact."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7603","DOI":"10.3748\/wjg.v26.i48.7603","article-title":"Gut microbiota mediated molecular events and therapy in liver diseases","volume":"26","author":"Qi","year":"2020","journal-title":"World J. Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J. Clin. Exp. Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.cegh.2015.10.005","article-title":"Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis","volume":"3","author":"Singh","year":"2015","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e23217","DOI":"10.1002\/jbt.23217","article-title":"Exploration of the underlying mechanisms of isoniazid\/rifampicin\u2010induced liver injury in mice using an integrated proteomics and metabolomics approach","volume":"36","author":"Song","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1270041","DOI":"10.3389\/fnins.2024.1270041","article-title":"1H-NMR metabolomics investigation of CSF from children with HIV reveals altered neuroenergetics due to persistent immune activation","volume":"18","author":"Thirion","year":"2024","journal-title":"Front. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"114843","DOI":"10.1016\/j.jpba.2022.114843","article-title":"Combined 1H NMR fecal metabolomics and 16S rRNA gene sequencing to reveal the protective effects of Gushudan on kidney-yang-deficiency-syndrome rats via gut-kidney axis","volume":"217","author":"Tong","year":"2022","journal-title":"J. Pharm. Biomed. Analysis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug\u2010induced hepatotoxicity: concise up\u2010to\u2010date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J. Gastroenterology Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jinf.2020.06.078","article-title":"Metabolic characterization of tuberculous meningitis in a South African paediatric population using 1H NMR metabolomics","volume":"81","author":"Van Zyl","year":"2020","journal-title":"J. Infect."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1095438","DOI":"10.3389\/fendo.2022.1095438","article-title":"Dysbiosis of gut microbiota and decreased propionic acid associated with metabolic abnormality in Cushing\u2019s syndrome","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Endocrinol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1661938\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:28:07Z","timestamp":1763360887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1661938\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":24,"alternative-id":["10.3389\/fphar.2025.1661938"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1661938","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1661938"}}